Latest filing published 30 Mar 2026 for LABCORP HOLDINGS INC..
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Brian J. Caveney, EVP, President of Diagnostics at Labcorp Holdings Inc., filed 80 disclosures between February 14, 2019 and March 30, 2026, all at Labcorp Holdings Inc. The record holds 2 purchases, EUR 10,255 (September 7, 2022) and EUR 9,509 (June 7, 2022), EUR 19,765 in total and half of market trades, and 2 sales, EUR 433,925 (June 3, 2025) and EUR 364,137 (February 24, 2026), EUR 798,062.
The rest is 44 share grants and 32 option exercises. The year 2022 is the busiest with 14 filings; 2026 already has 13, 2019 only 2. Thirteen filings fall in the last twelve months, 1 of them a sale. Median publication delay: 3 days, across 80 dated filings.
At Labcorp Holdings Inc., Adam H. Schechter has 2 trades within 30 days of Caveney's; Jonathan C. Meltzer, Kerrii B. Anderson, Peter J. Wilkinson and Sandra D. van der Vaart have 1 each, all in the same direction.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 80 declarations